Literature DB >> 23444222

CD44 and OTP are strong prognostic markers for pulmonary carcinoids.

Dorian R A Swarts1, Mieke E R Henfling, Leander Van Neste, Robert-Jan van Suylen, Anne-Marie C Dingemans, Winand N M Dinjens, Annick Haesevoets, Martina Rudelius, Erik Thunnissen, Marco Volante, Wim Van Criekinge, Manon van Engeland, Frans C S Ramaekers, Ernst-Jan M Speel.   

Abstract

PURPOSE: Pulmonary carcinoids are well-differentiated neuroendocrine tumors showing usually a favorable prognosis. However, there is a risk for late recurrence and/or distant metastasis. Because histologic classification in typical and atypical carcinoids is difficult and its reliability to predict disease outcome varies, we evaluated three genes as potential prognostic markers, that is, orthopedia homeobox (OTP), CD44, and rearranged during transfection (RET). EXPERIMENTAL
DESIGN: These genes were analyzed in 56 frozen carcinoids by quantitative real-time PCR (qRT-PCR). RET was further studied by methylation and mutation analysis. Immunohistochemistry for CD44 and OTP protein expression was conducted on 292 carcinoids.
RESULTS: Low mRNA expression levels of CD44 (P = 1.8e(-5)) and OTP (P = 0.00054), and high levels of RET (P = 0.025), were strongly associated with a low 20-year survival of carcinoid patients. High RET expression was not related to promoter hypomethylation or gene mutations. A direct link between gene expression and protein levels was confirmed for CD44 and OTP but not for RET. Within all carcinoids as well as atypical carcinoids, absence of CD44 protein was significantly associated with low 20-year survival (P = 0.00014 and 0.00013, respectively). The absence of nuclear OTP followed by complete loss of expression was also significantly associated with unfavorable disease outcome in all carcinoids (P = 5.2(-6)). Multivariate analyses revealed that age at diagnosis, histopathology, stage, and cytoplasmic OTP immunoreactivity were independent predictors of prognosis.
CONCLUSIONS: Our study indicates that CD44 and OTP are strong indicators of poor outcome. We therefore argue for implementation of these markers in routine diagnostics in addition to histopathology to improve subclassification of pulmonary carcinoids into prognostically relevant categories.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23444222     DOI: 10.1158/1078-0432.CCR-12-3078

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

Review 1.  Therapeutic biomarkers in lung neuroendocrine neoplasia.

Authors:  Luisella Righi; Marco Volante; Ida Rapa; Simona Vatrano; Giuseppe Pelosi; Mauro Papotti
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 2.  Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms.

Authors:  Irvin M Modlin; Mark Kidd; Pier-Luigi Filosso; Matteo Roffinella; Anna Lewczuk; Jaroslaw Cwikla; Lisa Bodei; Agnieska Kolasinska-Cwikla; Kyung-Min Chung; Margot E Tesselaar; Ignat A Drozdov
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  Prognostic Significance of CD44 and Orthopedia Homeobox Protein (OTP) Expression in Pulmonary Carcinoid Tumours.

Authors:  George Papaxoinis; Daisuke Nonaka; Ciara O'Brien; Benjamin Sanderson; Piotr Krysiak; Wasat Mansoor
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 4.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 5.  Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors.

Authors:  Dimitrios Moris; Ioannis Ntanasis-Stathopoulos; Diamantis I Tsilimigras; Mohamad A Adam; Chi-Fu Jeffrey Yang; David Harpole; Stamatios Theocharis
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

6.  Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.

Authors:  Alessandra Fabbri; Mara Cossa; Angelica Sonzogni; Mauro Papotti; Luisella Righi; Gaia Gatti; Patrick Maisonneuve; Barbara Valeri; Ugo Pastorino; Giuseppe Pelosi
Journal:  Virchows Arch       Date:  2017-01-04       Impact factor: 4.064

Review 7.  Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?

Authors:  Thomas Yang Sun; Andrew Hendifar; Sukhmani K Padda
Journal:  Curr Oncol Rep       Date:  2022-03-19       Impact factor: 5.945

Review 8.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

9.  Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Authors:  Giuseppe Pelosi; Fabrizio Bianchi; Elisa Dama; Michele Simbolo; Andrea Mafficini; Angelica Sonzogni; Sara Pilotto; Sergio Harari; Mauro Papotti; Marco Volante; Gabriella Fontanini; Luca Mastracci; Adriana Albini; Emilio Bria; Fiorella Calabrese; Aldo Scarpa
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

10.  Genes conserved in bilaterians but jointly lost with Myc during nematode evolution are enriched in cell proliferation and cell migration functions.

Authors:  Albert J Erives
Journal:  Dev Genes Evol       Date:  2015-07-15       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.